Egalet Corp. (NASDAQ:EGLT)’s share price was down 4.5% on Wednesday . The company traded as low as $6.94 and last traded at $6.96, with a volume of 73,425 shares trading hands. The stock had previously closed at $7.29.

A number of equities analysts recently weighed in on EGLT shares. Zacks Investment Research lowered Egalet Corp. from a “hold” rating to a “sell” rating in a research report on Tuesday, August 9th. Cantor Fitzgerald reiterated a “buy” rating on shares of Egalet Corp. in a research report on Tuesday, June 28th.

The firm’s market capitalization is $161.49 million. The company has a 50 day moving average price of $7.44 and a 200 day moving average price of $6.54.

Egalet Corp. (NASDAQ:EGLT) last issued its quarterly earnings data on Thursday, August 4th. The specialty pharmaceutical company reported ($0.97) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.82) by $0.15. The business earned $3.45 million during the quarter, compared to analysts’ expectations of $3.83 million. During the same period last year, the firm posted ($1.03) EPS. The business’s revenue was up 259.4% on a year-over-year basis. Equities research analysts predict that Egalet Corp. will post ($3.47) earnings per share for the current fiscal year.

In other news, CEO Robert S. Radie sold 15,000 shares of the business’s stock in a transaction on Wednesday, July 6th. The stock was sold at an average price of $5.01, for a total transaction of $75,150.00. Following the completion of the sale, the chief executive officer now owns 259,900 shares in the company, valued at $1,302,099. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Robert S. Radie sold 5,000 shares of the business’s stock in a transaction on Friday, July 1st. The stock was sold at an average price of $5.07, for a total value of $25,350.00. Following the sale, the chief executive officer now owns 259,900 shares of the company’s stock, valued at approximately $1,317,693. The disclosure for this sale can be found here.

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.